Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.35 |
| ▸ | SLC12A5 | Q9H2X9 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792988 | 0.78 | KMT2A (0.44) | KMT2AMEN1MAPTGAARAB9A | |
| SCHEMBL14942657 | 0.75 | KMT2A (0.35) | KMT2AMEN1MAPTLMNASMN1; SMN2 | |
| SCHEMBL21229023 | 0.74 | MEN1 (0.57) | KMT2AMEN1MAPTGAARAB9A | |
| SCHEMBL9955496 | 0.73 | SLC12A5 (0.49) | KMT2AMEN1MAPTGAARAB9A | |
| SCHEMBL21813075 | 0.71 | GRM1 (0.40) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL5879806 | 0.71 | UCHL1 (0.37) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL367981 | 0.71 | SMN1; SMN2 (0.51) | KMT2AMEN1GAARAB9ANPC1 | |
| SCHEMBL2909009 | 0.70 | RAB9A (0.39) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL1058191 | 0.70 | MMP1 (0.35) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL23723505 | 0.69 | SLC12A5 (0.46) | KMT2AMEN1MAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653141-B2 | HIV protease inhibiting compounds | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2264032-B1 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBVIE INC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| EP-2216334-B1 | HIV protease inhibiting sulfonamides | ABBOTT LAB (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2264032-A2 | Hiv protease inhibiting sulfonamides | Abbott Laboratories (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-2216334-A1 | Hiv protease inhibiting sulfonamides | Abbott Laboratories (US) | 2010-08-11 | — | — | EP | disclosed |
| EP-1709037-B1 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBOTT LAB (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20050131042-A1 | HIV protease inhibiting compounds | ABBOTT LABORATORIES | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | KMT2A 4151/4885MEN1 4515/4885MAPT 2176/4885 |
| US-20050131042-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | KMT2A 4151/4885MEN1 4515/4885MAPT 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.